scholarly journals A Pilot Study of the Association of Tumor Necrosis Factor Alpha Polymorphisms with Psoriatic Arthritis in the Romanian Population

2011 ◽  
Vol 12 (8) ◽  
pp. 5052-5059 ◽  
Author(s):  
Olivia M. Popa ◽  
Mihai Bojinca ◽  
Violeta Bojinca ◽  
Monica I. Dutescu ◽  
Mihaela Meirosu ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Pilot Study ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis Factor Alpha ◽  
Tumor Necrosis ◽  
Necrosis Factor Alpha ◽  
Factor Alpha ◽  
Romanian Population ◽  
Necrosis Factor

scholarly journals Adalimumab treatment leads to reduction of tissue tumor necrosis factor-alpha correlated with venous leg ulcer improvement: a pilot study

2015 ◽  
Vol 13 (5) ◽  
pp. 963-966 ◽  
Author(s):  
Joshua D Fox ◽  
Katherine L Baquerizo-Nole ◽  
Brian R Keegan ◽  
Flor Macquhae ◽  
Julia Escandon ◽  
...  
Keyword(s):  
Pilot Study ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis Factor Alpha ◽  
Tumor Necrosis ◽  
Venous Leg Ulcer ◽  
Necrosis Factor Alpha ◽  
Tissue Tumor ◽  
Adalimumab Treatment ◽  
Factor Alpha ◽  
Necrosis Factor

scholarly journals Effect of interleukin-17A inhibitor in Japanese patients with psoriatic arthritis compared with tumor necrosis factor-alpha inhibitor

2021 ◽  
Vol 29 (2) ◽  
pp. 230949902110122
Author(s):  
Takuya Izumiyama ◽  
Yu Mori ◽  
Itsuki Oizumi ◽  
Soshi Hamada ◽  
Hiroaki Kurishima ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Tumor Necrosis Factor ◽  
Disease Activity ◽  
Tumor Necrosis Factor Alpha ◽  
Tumor Necrosis ◽  
Japanese Patients ◽  
Necrosis Factor Alpha ◽  
Interleukin 17A ◽  
Factor Alpha ◽  
Necrosis Factor

Objectives: The patient of severe psoriatic arthritis (PsA) is mainly treated with oral methotrexate, ciclosporin, and anti-tumor necrosis factor-alpha inhibitors (TNFi). Recently, anti-interleukin-17A inhibitors (IL-17Ai) have been used in the treatment of PsA. This study aimed to evaluate the efficacy and safety of IL-17Ai in Japanese patients with PsA compared with those of TNFi. Methods: This was a longitudinal and retrospective study. The study population included 31 Japanese patients with PsA. All enrolled patients fulfilled the Classification Criteria for Psoriatic Arthritis. All patients were treated with TNFi or IL-17Ai. The assessed clinical manifestations were C-reactive protein (CRP)-based Disease Activity Score in 28 Joints (DAS28-CRP), disease activity in psoriatic arthritis (DAPSA), 20% achievement of American College of Rheumatology core set, swollen joint count (SJC), tender joint count (TJC), and visual analog scale (VAS). Functional ability of patients with PsA was analyzed using the modified health assessment questionnaire (mHAQ) score. We evaluated the parameters at baseline and weeks 12, 24, and 52. Results: The change in SJC, TJC, VAS, mHAQ, and DAPSA had no significant difference at weeks 12, 24, and 52. The improvements of CRP and DAS28-CRP were significantly higher in TNFi group only at week 12. The biologics retention rate was significantly higher in TNFi group by the log-rank test. No critical adverse events occurred. Conclusions: Our study presented that IL-17Ai had treatment effects comparable to TNFi. IL-17Ai might have the potential to become an alternative to the previous drug, but more large-scale studies are expected.

scholarly journals Tumor necrosis factor-alpha and interleukin-1 alpha as predictors of survival in peritonitis: A pilot study

2018 ◽  
Vol 24 (2) ◽  
pp. 107
Author(s):  
OludolapoOla Afuwape ◽  
OmobolajiO Ayandipo ◽  
Modupe Kuti ◽  
TA Adigun ◽  
OK Idowu
Keyword(s):  
Pilot Study ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis Factor Alpha ◽  
Tumor Necrosis ◽  
Interleukin 1 ◽  
Necrosis Factor Alpha ◽  
Factor Alpha ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document